Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An N-of-1 Double-blind Randomized Phase 1 Trial of the Safety and Feasibility of (Intermittent) Hypoxia Therapy in Parkinson's Disease (TALISMAN)

NCT05214287 is registered in ClinicalTrials.gov with Radboud University Medical Center as lead sponsor.

NCT NCT05214287
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05214287 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An N-of-1 Double-blind Randomized Phase 1 Trial of the Safety and Feasibility of (Intermittent) Hypoxia Therapy in Parkinson's Disease (TALISMAN)
Lead sponsor
Radboud University Medical Center
Phase
Phase 1/2
Overall status
Completed
Start date
February 22, 2022
Completion date
July 12, 2023
Enrollment
29 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

effect of drug, parkinson disease